Ultimovacs - UV1 Phase II data flow creeps closer
Management provided an update on the clinical progress of lead candidate UV1 in six clinical trials in conjunction with its Q122 financial results. Enrolment in the INITIUM (first-line metastatic malignant melanoma, UV1 dosed in combination with anti-CTLA-4 and PD-1 checkpoint inhibitors) and NIPU (second-line mesothelioma, plus ipilimumab and nivolumab) Phase II trials has reached 89% and 66%, respectively, keeping both on track to report primary endpoint (progression-free survival) readouts in H123. Furthermore, first patient enrolment for the anticipated Phase II LUNGVAC trial in first-line non-small cell lung cancer is anticipated in Q222, with an update expected in the Q422 report. At end-March 2022, Ultimovacs had a cash position of NOK523.7m which, at the current burn rate (NOK50.5m cash spent in Q123), we estimate will fund operations through the company’s the first four Phase II readouts (all expected by H124). Our estimates are under review.Ultimovacs ASA Formerly known as Ultimovacs AS. Ultimovacs ASA, formerly Ultimovacs AS, is a Norway-based pharmaceutical company developing immunotherapies against cancer. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. The Company is performing a broad clinical development program with clinical trials in Europe and the USA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.